Vir Biotechnology

Vir Biotechnology logo
🇺🇸United States
Ownership
Public
Established
2016-04-07
Employees
587
Market Cap
-
Website
http://www.vir.bio
Introduction

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

bdtonline.com
·

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial

Vir Biotechnology to provide Q3 2024 financial results and corporate update on Oct 31, 2024, with a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Information will be available on the Vir website and a recorded version will be archived for 30 days.
marketscreener.com
·

Vir Biotechnology Announces Clinical Advances across Hepatitis Delta and ...

Vir Biotechnology to present Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta at AASLD's The Liver Meeting in San Diego, Nov 15-19, 2024.
© Copyright 2024. All Rights Reserved by MedPath